Shandong Boan Biotechnology (HKG:6955) said its novel CD228-directed antibody-drug conjugate (ADC), BA1302, received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the treatment of squamous non-small cell lung cancer (sqNSCLC) and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.
BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.
The biopharmaceutical company's shares were up 2% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.